● Recruiting

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Condition: Pancreatic Ductal Adenocarcinoma · Sponsor: Onconic Therapeutics Inc.

PhasePhase 1/Phase 2

Planned participants71

Who can joinAll sexes, 19 Years to 79 Years

Healthy volunteersNo

About this study

The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and metastatic pancreatic cancer

This description comes directly from the study's public registry record.

Talk to the study team

OnconicTherapeutics · 82-2-3454-0780 · onconictherapeutics@gmail.com

Always discuss trial participation with your own doctor first.

Locations (4)

Seoul National University Bundang Hospital	Gyeonggi-do, South Korea	Recruiting
Samsung Medical Center	Seoul, South Korea	Recruiting
Seoul national university hospital	Seoul, South Korea	Recruiting
Severance Hospital	Seoul, South Korea	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05257993